{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:41:13Z","timestamp":1793032873687,"version":"4.5.0"},"reference-count":30,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000052","name":"NIH Office of the Director","doi-asserted-by":"publisher","award":["OT2OD028395"],"award-info":[{"award-number":["OT2OD028395"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alcohol, Clinical and Experimental Research"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Growing evidence suggests glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101RAs) may represent a novel potential pharmacotherapeutic tool for alcohol use disorder (AUD). The objective of this study is to examine the association between GLP\u20101RA prescriptions and alcohol use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This cohort study used a cross\u2010sectional measure of alcohol consumption and longitudinal electronic health record (EHR) data collected between 1981 and October 2023 from NIH's\n                      <jats:italic>All of Us<\/jats:italic>\n                      Research Program, a large program to recruit and collect surveys, EHR, genomic, and wearable data from a wide array of Americans. Among 15,447 participants with at least two recorded GLP\u20101RA prescriptions on separate days, we created three groups based on the timing of Alcohol Use Disorders Identification Test\u2010Consumption (AUDIT\u2010C) responses relative to first GLP\u20101RA prescription. This resulted in 3650 with current GLP\u20101RA prescriptions, 5642 with future GLP\u20101RAs (primary comparison group), and 544 with previous GLP\u20101RAs. AUDIT\u2010C scores were compared across these groups and to propensity\u2010score matched comparison groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Those with current GLP\u20101RA prescriptions had statistically significant but modestly lower AUDIT\u2010C scores compared with those with future prescriptions (incidence rate ratio [IRR]\u2009=\u20090.95; 95% CI: 0.91\u20130.99;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01). Participants with a previous GLP\u20101RA prescription had lower AUDIT\u2010C scores compared with those with future prescriptions, but this difference was not statistically significant. Results were similar using a matched comparison group with the current GLP\u20101RA group (IRR\u2009=\u20090.89; 95% CI: 0.85\u20130.93;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2264\u20090.001) and no significant difference for the previous prescription group. Analysis of individual AUDIT\u2010C questions shows a significant association with GLP\u20101RA prescriptions and frequency of drinking but not drinks per occasion or binge drinking.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study's findings indicate that GLP\u20101RAs may reduce alcohol consumption by decreasing use frequency. Experimental studies and randomized controlled trials are needed to test the mechanisms and potential efficacy of GLP\u20101RAs in people with AUD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/acer.70357","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:13:27Z","timestamp":1783588407000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of GLP\u20101 Receptor Agonist Prescriptions and Alcohol Consumption in the National Institutes of Health's\n                    <i>All of Us<\/i>\n                    Cohort"],"prefix":"10.1111","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5514-4149","authenticated-orcid":false,"given":"Benjamin","family":"Tyndall","sequence":"first","affiliation":[{"name":"RTI International  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Gasdaska","sequence":"additional","affiliation":[{"name":"RTI International  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Daniel","family":"Brannock","sequence":"additional","affiliation":[{"name":"RTI International  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Preble","sequence":"additional","affiliation":[{"name":"RTI International  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4423-797X","authenticated-orcid":false,"given":"Melissa","family":"McPheeters","sequence":"additional","affiliation":[{"name":"RTI International  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Marcial","sequence":"additional","affiliation":[{"name":"RTI International  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariba","family":"Huda","sequence":"additional","affiliation":[{"name":"RTI International  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Egan","sequence":"additional","affiliation":[{"name":"National Institutes of Health  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara R.","family":"Litwin","sequence":"additional","affiliation":[{"name":"National Institutes of Health  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Adjemian","sequence":"additional","affiliation":[{"name":"National Institutes of Health  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandan","family":"Sastry","sequence":"additional","affiliation":[{"name":"National Institutes of Health  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0902-4212","authenticated-orcid":false,"given":"Mehdi","family":"Farokhnia","sequence":"additional","affiliation":[{"name":"National Institutes of Health  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7284-8754","authenticated-orcid":false,"given":"Lorenzo","family":"Leggio","sequence":"additional","affiliation":[{"name":"National Institutes of Health  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1809937"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1995.tb02031.x"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13929"},{"key":"e_1_2_10_5_1","first-page":"821","article-title":"Two Brief Alcohol\u2010Screening Tests From the Alcohol Use Disorders Identification Test (AUDIT): Validation in a Female Veterans Affairs Patient Population","volume":"163","author":"Bradley K.","year":"2003","journal-title":"JAMA Internal Medicine"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2019.03.029"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107312"},{"key":"e_1_2_10_8_1","first-page":"1789","article-title":"The AUDIT Alcohol Consumption Questions (AUDIT\u2010C): An Effective Brief Screening Test for Problem Drinking","volume":"158","author":"Bush K.","year":"1998","journal-title":"JAMA Internal Medicine"},{"key":"e_1_2_10_9_1","unstructured":"Eli Lilly.\u201cMounjaro (Tirzepatide).\u201d[Package Insert; U.S. Food and Drug Administration Web Site].2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215866s039lbl.pdf."},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI188314"},{"key":"e_1_2_10_11_1","first-page":"188","article-title":"Charlson Comorbidity Index: ICD\u20109 Update and ICD\u201010 Translation","volume":"12","author":"Glasheen W.","year":"2019","journal-title":"American Health and Drug Benefits"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-015-1088-0"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.4789"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159863"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15677"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.3599"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02634-8"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19761"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.47644"},{"key":"e_1_2_10_20_1","article-title":"Assessing the Generalizability of Prevalence Estimates From the All of us Research Program","author":"Montgomery B.","year":"2026","journal-title":"American Journal of Epidemiology"},{"key":"e_1_2_10_21_1","unstructured":"National Institutes of Health.2025a.\u201cAll of Us Research Program: Curated Data Repository (CDR) Version 8 Release Notes [NIH Web Site].\u201dhttps:\/\/support.researchallofus.org\/hc\/en\u2010us\/articles\/30294451486356\u2010Curated\u2010Data\u2010Repository\u2010CDR\u2010version\u20108\u2010Release\u2010Notes."},{"key":"e_1_2_10_22_1","unstructured":"National Institutes of Health.2025b.\u201cAll of Us Research Program: Lifestyle: Baseline Survey Details and Resources [NIH Web Site].\u201dhttps:\/\/support.researchallofus.org\/hc\/en\u2010us\/articles\/6085586512660\u2010Lifestyle\u2010Baseline\u2010Survey\u2010Details\u2010and\u2010Resources."},{"key":"e_1_2_10_23_1","unstructured":"Novo Nordisk.2020.\u201cOzempic (Semaglutide). [Package Insert; U.S. Food and Drug Administration Web Site].\u201dhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209637s003lbl.pdf."},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.170419"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16679"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(19)30231-2"},{"key":"e_1_2_10_27_1","unstructured":"U.S. Centers for Disease Control and Prevention.2024.\u201cFacts About U.S. Deaths From Excessive Alcohol Use [CDC Web Site].\u201dhttps:\/\/www.cdc.gov\/alcohol\/facts\u2010stats\/index.html."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48780-6"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax4043"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13776"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03412-w"}],"container-title":["Alcohol, Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/acer.70357","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/acer.70357","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/acer.70357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:17:14Z","timestamp":1793031434000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/acer.70357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/acer.70357"],"URL":"https:\/\/doi.org\/10.1111\/acer.70357","archive":["Portico"],"relation":{},"ISSN":["2993-7175","2993-7175"],"issn-type":[{"value":"2993-7175","type":"print"},{"value":"2993-7175","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70357"}}